Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7647 | ARL 17477 dihydrochloride |
| Selective neuronal nitrogen oxide synthase (nNOS) inhibitor (IC50 values are 1 and 17 μM for nNOS and endothelial NOS respectively). Reduces ischemic cell damage after middle cerebral artery (MCA) occlusion in rats. Displays a synergistic neuroprotective effect when combined with either an NMDA or AMPA receptor antagonist. | |
| BCC7648 | QS 11 |
| GTPase activating protein of ADP-ribosylation factor 1 (ARFGAP1) inhibitor. Modulates ARF-GTP levels and synergizes with the Wnt/β-catenin signaling pathway to upregulate β-catenin nuclear translocation. Also reduces in vitro migration of metastatic human breast cancer cells. | |
| BCC7651 | Desformylflustrabromine hydrochloride |
| Positive allosteric modulator of nicotinic α4β2 receptors; selectively increases the ionic current through α4β2 in the presence of ACh. Displays 14.7-fold selectivity for α4β2 over homomeric (α7) receptors. Moderately cytotoxic in HCT-116 cells. Also inhibits human muscle (αβεδ) and Torpedo (αβγδ) nAChRs (IC50 values are 1.0 and 0.1 μM, respectively) by binding in the ion channel. | |
| BCC7655 | Ro 8-4304 hydrochloride |
| NMDA receptor antagonist (IC50 = 0.4 μM) that displays > 100 fold selectivity for NR2B-containing receptors over NR2A-containing receptors. Exhibits an activity-dependent mechanism of NMDA antagonism and is competitive with respect to spermine . | |
| BCC7658 | SNAP 94847 hydrochloride |
| Potent melanin-concentrating hormone receptor 1 (MCH1) antagonist (Ki = 2.2 nM, KD = 530 pM) that displays > 80-fold and > 500-fold selectivity over α1A and D2 receptors respectively. Increases neurogenesis in the dentate gyrus and decreases food-reinforced operant responding in vivo. Exhibits anxiolytic activity and is orally active. | |
| BCC7661 | NS 304 |
| Selective prostacyclin IP1 receptor agonist (Ki values are 260 and 2100 nM and for human and rat IP receptors, and >10 μM for EP1-4, DP, FP, and TP receptors). Prodrug for the active form of MRE 26. Ameliorates vascular endothelial dysfunction and increases femoral skin blood flow in rats. Orally available. | |
| BCC7663 | PSN 375963 hydrochloride |
| GPR119 receptor agonist (EC50 values are 8.4 and 7.9 μM at human and mouse receptors respectively). Displays similar potency to the endogenous ligand oleylethanolamide (OEA). | |
| BCC7667 | CGP 52411 |
| Selective inhibitor of the epidermal growth factor receptor (EGFR) (IC50 = 0.3 μM in vitro). Also inhibits and reverses the formation of Aβ42 fibers associated with Alzheimer's disease. Eliminates calcium influx potential when coincubated with amyloid β-peptide (1-42); reduces neurotoxicity by blocking Ca2+ influx into neuronal cells. | |
